-
Je něco špatně v tomto záznamu ?
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
M. Dreyling, W. Jurczak, M. Jerkeman, RS. Silva, C. Rusconi, M. Trneny, F. Offner, D. Caballero, C. Joao, M. Witzens-Harig, G. Hess, I. Bence-Bruckler, SG. Cho, J. Bothos, JD. Goldberg, C. Enny, S. Traina, S. Balasubramanian, N. Bandyopadhyay, S....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
Nursing & Allied Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest) od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Odkazy
PubMed
26673811
DOI
10.1016/s0140-6736(15)00667-4
Knihovny.cz E-zdroje
- MeSH
- antitumorózní látky škodlivé účinky terapeutické užití MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfom z plášťových buněk farmakoterapie patologie MeSH
- pyrazoly škodlivé účinky terapeutické užití MeSH
- pyrimidiny škodlivé účinky terapeutické užití MeSH
- recidiva MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sirolimus škodlivé účinky analogy a deriváty terapeutické užití MeSH
- staging nádorů MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
BACKGROUND: Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma. METHODS: This randomised, open-label, multicentre, phase 3 clinical trial enrolled patients with relapsed or refractory mantle-cell lymphoma confirmed by central pathology in 21 countries who had received one or more rituximab-containing treatments. Patients were stratified by previous therapy and simplified mantle-cell lymphoma international prognostic index score, and were randomly assigned with a computer-generated randomisation schedule to receive daily oral ibrutinib 560 mg or intravenous temsirolimus (175 mg on days 1, 8, and 15 of cycle 1; 75 mg on days 1, 8, and 15 of subsequent 21-day cycles). Randomisation was balanced by using randomly permuted blocks. The primary efficacy endpoint was progression-free survival assessed by a masked independent review committee with the primary hypothesis that ibrutinib compared with temsirolimus significantly improves progression-free survival. The analysis followed the intention-to-treat principle. The trial is ongoing and is registered with ClinicalTrials.gov (number NCT01646021) and with the EU Clinical Trials Register, EudraCT (number 2012-000601-74). FINDINGS: Between Dec 10, 2012, and Nov 26, 2013, 280 patients were randomised to ibrutinib (n=139) or temsirolimus (n=141). Primary efficacy analysis showed significant improvement in progression-free survival (p<0·0001) for patients treated with ibrutinib versus temsirolimus (hazard ratio 0·43 [95% CI 0·32-0·58]; median progression-free survival 14·6 months [95% CI 10·4-not estimable] vs 6·2 months [4·2-7·9], respectively). Ibrutinib was better tolerated than temsirolimus, with grade 3 or higher treatment-emergent adverse events reported for 94 (68%) versus 121 (87%) patients, and fewer discontinuations of study medication due to adverse events for ibrutinib versus temsirolimus (9 [6%] vs 36 [26%]). INTERPRETATION: Ibrutinib treatment resulted in significant improvement in progression-free survival and better tolerability versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma. These data lend further support to the positive benefit-risk ratio for ibrutinib in relapsed or refractory mantle-cell lymphoma. FUNDING: Janssen Research & Development, LLC.
Champalimaud Centre for the Unknown Hematology Department Lisbon Portugal
Department of Hematology Jagiellonian University Krakow Poland
Department of Medicine 3 Klinikum der Universität München Campus Grosshadern Munich Germany
Derriford Hospital Plymouth Devon UK
Instituto Biosanitario de Salamanca Hospital Clinico Universitario Salamanca Salamanca Spain
Instituto De Ensino E Pesquisa São Lucas São Paulo Brazil
Instituto Português de Oncologia Lisbon Portugal
Janssen Research and Development LLC Leiden The Netherlands
Janssen Research and Development LLC Raritan NJ USA
Janssen Research and Development LLC Spring House PA USA
Klinikum der Ruprechts Karls Universität Heidelberg Med Klinik u Poliklinik 5 Heidelberg Germany
Seoul St Mary's Hospital Seocho gu Seoul South Korea
Skånes Universitetssjukhus Lund Lund Sweden
The Ottawa Hospital General Campus Ottawa Hospital General Campus Ottawa Canada
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16009899
- 003
- CZ-PrNML
- 005
- 20160415110025.0
- 007
- ta
- 008
- 160408s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S0140-6736(15)00667-4 $2 doi
- 024 7_
- $a 10.1016/S0140-6736(15)00667-4 $2 doi
- 035 __
- $a (PubMed)26673811
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Dreyling, Martin $u Department of Medicine III, Klinikum der Universität München, Campus Grosshadern, Munich, Germany. Electronic address: Martin.Dreyling@med.uni-muenchen.de.
- 245 10
- $a Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study / $c M. Dreyling, W. Jurczak, M. Jerkeman, RS. Silva, C. Rusconi, M. Trneny, F. Offner, D. Caballero, C. Joao, M. Witzens-Harig, G. Hess, I. Bence-Bruckler, SG. Cho, J. Bothos, JD. Goldberg, C. Enny, S. Traina, S. Balasubramanian, N. Bandyopadhyay, S. Sun, J. Vermeulen, A. Rizo, S. Rule,
- 520 9_
- $a BACKGROUND: Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma. METHODS: This randomised, open-label, multicentre, phase 3 clinical trial enrolled patients with relapsed or refractory mantle-cell lymphoma confirmed by central pathology in 21 countries who had received one or more rituximab-containing treatments. Patients were stratified by previous therapy and simplified mantle-cell lymphoma international prognostic index score, and were randomly assigned with a computer-generated randomisation schedule to receive daily oral ibrutinib 560 mg or intravenous temsirolimus (175 mg on days 1, 8, and 15 of cycle 1; 75 mg on days 1, 8, and 15 of subsequent 21-day cycles). Randomisation was balanced by using randomly permuted blocks. The primary efficacy endpoint was progression-free survival assessed by a masked independent review committee with the primary hypothesis that ibrutinib compared with temsirolimus significantly improves progression-free survival. The analysis followed the intention-to-treat principle. The trial is ongoing and is registered with ClinicalTrials.gov (number NCT01646021) and with the EU Clinical Trials Register, EudraCT (number 2012-000601-74). FINDINGS: Between Dec 10, 2012, and Nov 26, 2013, 280 patients were randomised to ibrutinib (n=139) or temsirolimus (n=141). Primary efficacy analysis showed significant improvement in progression-free survival (p<0·0001) for patients treated with ibrutinib versus temsirolimus (hazard ratio 0·43 [95% CI 0·32-0·58]; median progression-free survival 14·6 months [95% CI 10·4-not estimable] vs 6·2 months [4·2-7·9], respectively). Ibrutinib was better tolerated than temsirolimus, with grade 3 or higher treatment-emergent adverse events reported for 94 (68%) versus 121 (87%) patients, and fewer discontinuations of study medication due to adverse events for ibrutinib versus temsirolimus (9 [6%] vs 36 [26%]). INTERPRETATION: Ibrutinib treatment resulted in significant improvement in progression-free survival and better tolerability versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma. These data lend further support to the positive benefit-risk ratio for ibrutinib in relapsed or refractory mantle-cell lymphoma. FUNDING: Janssen Research & Development, LLC.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a antitumorózní látky $x škodlivé účinky $x terapeutické užití $7 D000970
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a lymfom z plášťových buněk $x farmakoterapie $x patologie $7 D020522
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a pyrazoly $x škodlivé účinky $x terapeutické užití $7 D011720
- 650 _2
- $a pyrimidiny $x škodlivé účinky $x terapeutické užití $7 D011743
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a sirolimus $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D020123
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jurczak, Wojciech $u Department of Hematology, Jagiellonian University, Krakow, Poland.
- 700 1_
- $a Jerkeman, Mats $u Skånes Universitetssjukhus, Lund, Lund, Sweden.
- 700 1_
- $a Silva, Rodrigo Santucci $u Instituto De Ensino E Pesquisa São Lucas, São Paulo, Brazil.
- 700 1_
- $a Rusconi, Chiara $u Hematology Division, Hematology and Oncology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
- 700 1_
- $a Trneny, Marek $u Vseobecna fakultni nemocnice, Interni Klinika-Klinika Hematologie, Urologicka klinika, Prague, Czech Republic.
- 700 1_
- $a Offner, Fritz $u UZ Gent-Departement Oncologie, Gent, Belgium.
- 700 1_
- $a Caballero, Dolores $u Instituto Biosanitario de Salamanca, Hospital Clinico Universitario Salamanca, Salamanca, Spain.
- 700 1_
- $a Joao, Cristina $u Champalimaud Centre for the Unknown, Hematology Department, Lisbon, Portugal; Instituto Português de Oncologia, Lisbon, Portugal.
- 700 1_
- $a Witzens-Harig, Mathias $u Klinikum der Ruprechts-Karls-Universität Heidelberg-Med. Klinik u. Poliklinik V, Heidelberg, Germany.
- 700 1_
- $a Hess, Georg $u University Medical School of the Johannes Gutenberg-University, Department of Hematology, Oncology and Pneumology, Mainz, Germany.
- 700 1_
- $a Bence-Bruckler, Isabelle $u The Ottawa Hospital-General Campus, Ottawa-Hospital General Campus, Ottawa, Canada.
- 700 1_
- $a Cho, Seok-Goo $u Seoul St Mary's Hospital, Seocho-gu, Seoul, South Korea.
- 700 1_
- $a Bothos, John $u Janssen Research & Development, LLC, Raritan, NJ, USA.
- 700 1_
- $a Goldberg, Jenna D $u Janssen Research & Development, LLC, Raritan, NJ, USA.
- 700 1_
- $a Enny, Christopher $u Janssen Research & Development, LLC, Raritan, NJ, USA.
- 700 1_
- $a Traina, Shana $u Janssen Research & Development, LLC, Raritan, NJ, USA.
- 700 1_
- $a Balasubramanian, Sriram $u Janssen Research & Development, LLC, Spring House, PA, USA.
- 700 1_
- $a Bandyopadhyay, Nibedita $u Janssen Research & Development, LLC, Raritan, NJ, USA.
- 700 1_
- $a Sun, Steven $u Janssen Research & Development, LLC, Raritan, NJ, USA.
- 700 1_
- $a Vermeulen, Jessica $u Janssen Research & Development, LLC, Leiden, The Netherlands.
- 700 1_
- $a Rizo, Aleksandra $u Janssen Research & Development, LLC, Raritan, NJ, USA.
- 700 1_
- $a Rule, Simon $u Derriford Hospital, Plymouth, Devon, UK.
- 773 0_
- $w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 387, č. 10020 (2016), s. 770-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26673811 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160415110110 $b ABA008
- 999 __
- $a ok $b bmc $g 1113328 $s 934267
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 387 $c 10020 $d 770-8 $e 20151207 $i 1474-547X $m Lancet $n Lancet $x MED00010161
- LZP __
- $a Pubmed-20160408